Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more insurers to cover the drug.
礼来制药(Eli Lilly)周三表示，该公司的减肥药替尔泊肽(tizepatide)在一项后期临床试验中显著减少了睡眠呼吸暂停问题，为鼓励更多保险公司承保该药提供了更多证据。
您已阅读7%（321字），剩余93%（4589字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。